Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease

Authors

Edilio Borroni
Bernd Bohrmann
Fiona Grueninger
Eric Prinssen
Stephane Nave
Hansruedi Loetscher
Shankar J. Chinta, Touro University CaliforniaFollow

Document Type

Article

Publication Date

2017

Publication Title

The Journal of Pharmacology and Experimental Therapeutics

DOI

10.1124/jpet.117.241653

Comments

Please see the work itself for the complete list of authors.

Recommended Citation

Borroni, E., Bohrmann, B., Grueninger, F., Prinssen, E., Nave, S., Loetscher, H., . . . Cesura, A. M. (2017). Sembragiline: A novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics, 362(3), 413-423. doi:10.1124/jpet.117.241653

Publisher's Statement

The original material can be found here: https://doi.org/10.1124/jpet.117.241653